Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 208-211

  Cho, Sung Joon ^a   Yook, Keunyoung ^a   Kim, Borah ^a   Choi, Tai Kiu ^a   Lee, Kang Soo ^a   Kim, Yong Woo ^a   Lee, Ji Eun ^a   Suh, ShinYoung ^a   Yook, Ki Hwan ^a   Lee, Sang Hyuk ^a  

^a CHA University   (South Korea)

Author keywords

Cognition; Mirtazapine; Negative symptom; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE; MIRTAZAPINE; PLACEBO; RISPERIDONE;

ADJUVANT THERAPY; ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; COGNITIVE DEFECT; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEMALE; HUMAN; LINGUISTICS; MALE; NEGATIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SHORT TERM MEMORY; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 78650943515     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.006     Document Type: Article

References (18)

1. Abbasi S.H., Behpournia H., Ghoreshi A., Salehi B., Raznahan M., Rezazadeh S.A., et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010, 116:101-106.
2. Andreasen N.C. The diagnosis of schizophrenia. Schizophr Bull 1987, 13:9-22.
3. Berk M., Ichim C., Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87-92.
4. Berk M., Gama C.S., Sundram S., Hustig H., Koopowitz L., D'Souza R., et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009, 24:233-238.
5. Delle Chiaie R., Salviati M., Fiorentini S., Biondi M. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 2007, 15:563-568.
6. Duinkerke S.J., Botter P.A., Jansen A.A., van Dongen P.A., van Haaften A.J., Boom A.J., et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 1993, 163:451-455.
7. Guy W. Patient assessment in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 1982, 6:601-606.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
9. Joffe G., Terevnikov V., Joffe M., Stenberg J.H., Burkin M., Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 2009, 108:245-251.
10. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
11. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., et al. 3rd. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 1999, 156:1871-1878.
12. Nakayama K., Sakurai T., Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 2004, 63:237-241.
13. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
14. Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for Axis I DSM-IV Disorder (SCID) 1995, American psychiatric Association, Washington, DC.
15. Stahl S.M. Stahl's essential psychopharmacology 2008, 559-565. Cambridge University Press, New York, NY. 3rd ed. S.M. Stahl (Ed.).
16. Stenberg J.H., Terevnikov V., Joffe M., Tiihonen J., Tchoukhine E., Burkin M., et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol 2010, 13(4):433-441.
17. Zhang Z.J., Kang W.H., Li Q., Wang X.Y., Yao S.M., Ma A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 2006, 88:102-110.
18. Zoccali R., Muscatello M.R., Cedro C., Neri P., La Torre D., Spina E., et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004, 19:71-76.